Abstract 1722P
Background
Adherence to guidelines is linked to favorable prognosis in various cancer types. Nevertheless, the increasing complexity and sophistication of cancer drug therapy have posed challenges in identifying evidence-based treatment options. Thus, patients with cancer and local physicians are increasingly resorting to the cancer center's second opinion (SO) system for advice on treatment strategies. Integrating academic opinions from multiple physicians via SOs is expected to improve the evidence compliance rate (ECR). However, it remains unclear which cases would benefit from SOs to enhance the ECR. This study aimed to identify the factors contributing to the differences in ECR in patients with cancer.
Methods
A single-center retrospective study was conducted at the Department of Medical Oncology, National Cancer Center Hospital (Tokyo, Japan), analyzing electronic medical records of 305 patients with cancer who received SOs between January and June 2022. Two medical oncologists evaluated ECR according to the latest international standard guidelines for each cancer and classified them into two levels (Compliance: ECR is ≧50%, Non-compliance: ECR is <50%).
Results
Of 305 cases referred from 130 hospitals, 247 (81%) were female; the median age was 56 years (range: 15–85). Among them, 150 (49.2%)/152 (49.8%) were common/rare cancers, with 95 (31%) having gynecological cancers, 84 (28%) having breast cancers, and 66 (22%) having mesothelial and soft tissue cancers as major groups. After excluding cancer types for which no guidelines existed, 214 cases were eventually analyzed. Japan had a significantly higher ECR with designated core or designated hospitals for cancer genomic medicine (p=0.036). No significant relationship was found between ECR and hospital types, such as oncology, university, or urban hospitals. Moreover, no significant relationship was found between ECR and cancer types and who requested the SO.
Conclusions
This study highlights differences in ECR based on referral hospital type. The findings may aid in the appropriate allocation of medical resources between cancer centers and local hospitals as online medical care networks become more prevalent in the future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1706P - Time to full approval of novel anticancer medicines granted accelerated approval and implications for reform of the accelerated approval pathway
Presenter: Thomas Hwang
Session: Poster session 23
1707P - Cancer drug prices in the US: Efficacy, innovation, clinical trial evidence, and epidemiology
Presenter: Christoph Michaeli
Session: Poster session 23
1708P - The registration pathways in China for globally developed novel anticancer drugs
Presenter: Da-wei Wu
Session: Poster session 23
1709P - Influence of censoring on conclusions of FDA-approved cancer drugs using the modified time to treatment failure
Presenter: Jonathan Ofer
Session: Poster session 23
1710P - Protocol waivers and consequences on treatment safety and efficacy in the Drug Rediscovery Protocol (DRUP)
Presenter: Laurien Zeverijn
Session: Poster session 23
1711P - The DRUP-like clinical trials family: A distributed European trial network for equitable access to precision medicine
Presenter: Hans Gelderblom
Session: Poster session 23
1712P - Implementation of a molecular pre-screening program (MPP) in a network of public cancer centres for phase I clinical trial (Ph1-CT) candidates: The PREICO program
Presenter: Juan José Soto Castillo
Session: Poster session 23
1713P - Non-inferiority oncology clinical trials in major journals: Purposes, methods and results
Presenter: Rafael Barreto
Session: Poster session 23
1714P - Geographical disparities in access to cancer clinical trials in Korea
Presenter: Sokbom Kang
Session: Poster session 23
1715P - Analysis of the adequacy of control arms in oncology randomized clinical trials published between 2017 and 2021: A meta-research study
Presenter: Alessandro Rossi
Session: Poster session 23